Search

Your search keyword '"Forman, S."' showing total 729 results

Search Constraints

Start Over You searched for: Author "Forman, S." Remove constraint Author: "Forman, S." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
729 results on '"Forman, S."'

Search Results

1. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

2. Relating the long-term and short-term vertical deformation across a transect of the forearc in the central Mexican subduction zone

3. LB1702 Lebrikizumab does not impact vaccine-induced immune responses: Results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis

6. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice:: GLORIA-AF Registry

7. P1296: SUPPRESSING SYNTHESIS OF THE LONG ISOFORM OF THE PROLACTIN RECEPTOR IS A TARGETED STRATEGY TO TREAT AUTOIMMUNE B-LYMPHOPROLIFERATIVE DISEASES AND B CELL MALIGNANCIES

8. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary

10. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

17. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

18. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

23. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

26. Elevated D-Dimer Levels are Associated with Increased Risk of Mortality in COVID-19: A Systematic Review and Meta-Analysis

28. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

29. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

32. Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation

38. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials

41. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

43. Edoxaban versus warfarin in patients with atrial fibrillation

44. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial

47. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

48. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

49. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

50. Practice guideline for the treatment of patients with eating disorders (revision). American Psychiatric Association Work Group on Eating Disorders

Catalog

Books, media, physical & digital resources